KNSA Stock: Kiniksa Pharmaceuticals, Ltd. Stock Price, Analysis & Insights
Get live KNSA stock price $49.56, comprehensive Kiniksa Pharmaceuticals, Ltd. stock analysis, charts, news, and expert forecast. Real-time KNSA stock data and investment insights.
Loading chart data...
Kiniksa Pharmaceuticals, Ltd. (KNSA) Overview
Kiniksa Pharmaceuticals, Ltd. (KNSA) is a publicly traded company in the Healthcare sector , specifically within the Biotechnology industry . As of the latest trading session, KNSA trades at $49.56 with a market capitalization of 3.73B . Over the past 52 weeks, KNSA has traded between $26.27 and $59.87 , with the current price positioned at approximately 69% of this range . The stock currently ...
Key Takeaways
- Operates in the Healthcare sector (Biotechnology)
- Market cap: 3.73B
- Current price: $49.56
- 52-week range: $26.27 - $59.87
- P/E ratio: 54.46
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Kiniksa Pharmaceuticals, Ltd. is a global biopharmaceutical firm dedicated to discovering, acquiring, advancing, and commercializing medical therapies for individuals suffering from severe illnesses where current treatment options are insufficient. I...
Company Information
- CEO
- Sanj K. Patel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 315
Contact Information
- Website
- https://www.kiniksa.com
- Address
- Clarendon House
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 54.5)
✓ Lower volatility stock (Beta: 0.12) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Kiniksa Pharmaceuticals, Ltd. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Kiniksa Pharmaceuticals, Ltd.
- ⚠Investors should consider how Kiniksa Pharmaceuticals, Ltd. fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 54.5) requires strong growth to justify
Market Cap
3.73B
P/E Ratio (TTM)
54.46
Beta
0.12
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare KNSA with peer companies:
- Price
- $17.99
- Market cap
- 2.88B
- Price
- $41.03
- Market cap
- 5.25B
- Price
- $221.38
- Market cap
- 5.61B
- Price
- $31.35
- Market cap
- 3.84B
- Price
- $14.49
- Market cap
- 4.55B
- Price
- $27.41
- Market cap
- 2.41B
- Price
- $24.37
- Market cap
- 1.62B
- Price
- $46.38
- Market cap
- 5.56B
- Price
- $49.20
- Market cap
- 3.93B
- Price
- $17.45
- Market cap
- 1.96B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.